Clinical Trial Update: PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for a PD-1 antibody aimed at preventing adenomatous polyps and second primary tumors in Lynch syndrome patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lynch Syndrome

Drugs mentioned

• PD-1 antibody (PD-1 inhibitor)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Lynch Syndrome | Phase 3 | Status: UNKNOWN